Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 138 (RNF138) is an E3 ubiquitin-protein ligase that mediates protein ubiquitination, thereby signaling proteins for degradation via the proteasome. It is involved in DNA damage response and repair by promoting homologous recombination, regulates transcription by targeting key transcription factors like C/EBPα, and is implicated in the differentiation arrest of myeloid cells in acute myeloid leukemia. RNF138 also modulates the NF-κB signaling pathway, with downregulation linked to poorer prognosis and increased tumor progression in diseases such as colorectal cancer. RNF138 is a member of the RING finger protein family characterized by the RING domain, essential for substrate protein recognition and E2-E3 ligase activity. Its dysfunction is associated with cancer, immune dysregulation, and potentially neurodegenerative conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ring finger protein 138 (RNF138).